The new guidelines classify heart failure (HF) into three subgroups based on the ejection
fraction (EF): HF with reduced EF (HFrEF), HF with mid-range EF (HFmrEF), and HF with …

Heart failure (HF) is a complex syndrome caused by a variety of structural or functional
cardiac abnormalities as a consequence of several involved pathophysiological pathways …

Background Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous
syndrome, with several underlying etiologic and pathophysiologic factors. The presence of …

Aim: The effect of sacubitril-valsartan (ARNI) in heart failure (HF) patients with mid-range
ejection fractions (HFmrEF) remains unclear. This study aimed to investigate the effects of …

Heart failure (HF) is one of the leading causes of morbidity and mortality worldwide.
Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has been approved for the …

Heart failure (HF) is the cause of impaired exercise capacity due to insufficient peripheral
blood flow. The development of natriuretic peptide (NP) through inhibition of the neprilysin …

Heart failure with mid-range ejection fraction (HFmrEF) was first proposed by Lam and
Solomon in 2014, and was listed as a new subtype of heart failure (HF) in 2016 European …

Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) was recently recognised as
a distinct clinical entity. Although guideline diagnostic criteria for HFmrEF are well defined …

Background The impact of sacubitril–valsartan on heart failure (HF) patients with preserved
ejection fractions (HFpEF) is uncertain. The purpose of this meta-analysis was to explore the …

This review aimed to summarize the adverse events (AEs) reported during the use of
sacubitril/valsartan versus angiotensin converting enzyme inhibitors (ACEI)/angiotensin II …